HSBC Holdings’s Palvella Therapeutics PVLA Stock Holding History

HSBC Holdings’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.64M	Buy	+50,001	New	+$6.07M	﹤0.01%	1058
2023 Q3	–	Sell	-202	Closed	-$2.72K	–	2879
2023 Q2	$2.72K	Hold	202	–	–	﹤0.01%	2541
2023 Q1	$15.8K	Hold	202	–	–	﹤0.01%	2617
2022 Q4	$15.2K	Sell	202 -44	-18%	-$3.54K	﹤0.01%	3024
2022 Q3	$22K	Sell	246 -6	-2%	-$774	﹤0.01%	2867
2022 Q2	$39K	Sell	252 -5	-2%	-$912	﹤0.01%	3161
2022 Q1	$63K	Buy	257 +92	+56%	+$24.2K	﹤0.01%	3182
2021 Q4	$50K	Hold	165	–	–	﹤0.01%	3201
2021 Q3	$70K	Buy	+165	New	+$57.5K	﹤0.01%	2915

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

HSBC Holdings's PVLA Position: Q2 2026 in Review

HSBC Holdings opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 50,001 shares worth $7.64M. The stake represents ﹤0.01% of the portfolio and ranks #1058 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in PVLA as recently as Q2 2023.

HSBC Holdings first reported a position in PVLA in Q3 2021 and has held it in 9 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

HSBC Holdings held 50,001 shares of Palvella Therapeutics worth $7.64M as of Q2 2026.
Palvella Therapeutics was a new HSBC Holdings position in Q2 2026.
Palvella Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #1058 holding.
HSBC Holdings first reported a position in Palvella Therapeutics in Q3 2021 and has held it in 9 quarters since.
196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.